Tg Therapeutics (TGTX) Stock Price, Quote & News

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 554 4484

Fax: 212 554 4531

Website: www.tgtherapeutics.com

Address:

3020 Carrington Mill Blvd., Suite 475, Morrisville, United States

RandandKaren May. 10 at 3:58 PM

$TGTX happy Mother’s Day All. One thing no one is talking about is that we are now the dynamic market share leader. The fact that this ragtag company is winning the tug-of-war with O and K is a pretty big freaking deal. Invalidates what all of us have been saying and modeling over the past few years. safer, faster, more effective, less expensive is winning just like we thought! I believe/hope this plus the near term catalysts is a permanent rerating and not a short term pop. As far as BO hopers go I believe it is still a possibility but more likely as we show subQ and/or B as a platform data

0 · Reply

ChartistMoM May. 10 at 3:32 PM

$TGTX My son forgot about Mother’s Day! I pay off his margarine calls and this is the thanks I get. Hey, call your mom and tell her you love her! My son certainly won’t. 😪

2 · Reply

Gshc22 May. 10 at 3:03 PM

$TGTX Is $ 40 ( or $42-43) the new $ 30 ? From now on, will TGTX be trading in the 40's range and leave $ 30' range for good ? Hopefully yes but we are never immune to an attack bringing us ( temporarily) to $ 30's range. Anyway, TGTX is on the right path. WS reacted positively (more than I was expecting I admit) after Q1 which is known to be the weakest quarter of the year. It bodes well for the rest of the year.

1 · Reply

DragonAlgoTrades May. 10 at 8:39 AM

🐉 $TGTX CALL — DragonAlgo® Signal Contract: TGTX CALL Expiry: 2026-05-15 | Strike: $37.00 | Type: CALL Option Plan (premium): Entry: $6.00 Stop: $4.32 TP1: $7.80 TP2: $10.20 TP3: $14.40 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

ACES_ May. 9 at 6:34 PM

$TGTX Just hold... dont worry.. be happy.. https://youtu.be/d-diB65scQU?si=aB0B6uzEWmbPRJi-

2 · Reply

Bobes May. 9 at 2:21 PM

$TGTX the stock is getting rerated. Its been trading in the 20s to 30s since people doubted they could compete against O and K. Now that is in the rear review we will move to the 40s and 50s. Once Azer Cell and Sub Q data comes in we move to the 60s. It may get bought as few drugs can deliver the type of revenue this one can. We are fine and dont stress the day to day movements.

6 · Reply

Thurmond May. 9 at 2:07 PM

$TGTX Some will jump up and down saying it is or going into overbought territory. Remember hard trending stocks can stay overbought for a long time destroying short positions (Mr. Market is never wrong); and you have to ask, what time frame is it overbought as right now the monthly looks fantastic, far from overbought, and that is what many long-term investors, traders, and institutions watch.

1 · Reply

jmartin795 May. 9 at 11:06 AM

$TGTX Morning. When was the last time we saw 400k in AH trading?

2 · Reply

StockDreamin May. 9 at 4:33 AM

$TGTX Maybe maybe someday!

1 · Reply

TBLdude May. 8 at 10:23 PM

$TGTX cheers to the week… Happy Mother’s Day to the Mom’s…have a great weekend, and do something you love doing with someone you love

0 · Reply

TG Therapeutics reports Q1 EPS 12c, consensus 28c

2026-05-07T03:05:19.000Z - 3 days ago

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

May 6, 2026, 8:30 AM EDT - 4 days ago

TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 days ago

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Apr 30, 2026, 7:30 AM EDT - 10 days ago

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

2026-04-15T11:48:15.000Z - 25 days ago

TG Therapeutics completes enrollment in Briumvi trial

Apr 15, 2026, 7:30 AM EDT - 25 days ago

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

2026-03-19T12:01:33.000Z - 7 weeks ago

TG Therapeutics secures additional $500M in non-dilutive capital

2026-03-19T12:01:19.000Z - 7 weeks ago

TG Therapeutics board expands share repurchase program to $300M

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

2026-03-09T11:40:09.000Z - 2 months ago

TG Therapeutics announces publication of data from studies on Briumvi

Mar 9, 2026, 7:30 AM EDT - 2 months ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 6, 2026, 7:30 AM EST - 2 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

2026-03-02T12:24:58.000Z - 2 months ago

Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone

DTIL

Mar 2, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

Feb 26, 2026, 8:30 AM EST - 2 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025

2026-02-26T12:15:51.000Z - 2 months ago

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $897.64M

2026-02-26T12:08:07.000Z - 2 months ago

TG Therapeutics reports Q4 EPS 14c, consensus 33c

2026-02-26T12:06:42.000Z - 2 months ago

TG Therapeutics expects cash to fund business based on current operating plan

Feb 26, 2026, 7:00 AM EST - 2 months ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 23, 2026, 7:30 AM EST - 2 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

2026-02-17T12:40:17.000Z - 2 months ago

TG Therapeutics announces long-term data on Briumvi published in JAMA Neurology

Feb 8, 2026, 4:17 PM EST - 3 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 6, 2026, 7:30 AM EST - 3 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

2026-02-02T12:45:26.000Z - 3 months ago

TG Therapeutics price target lowered to $46 from $49 at JPMorgan

Jan 15, 2026, 10:31 AM EST - 4 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

2026-01-15T00:55:09.000Z - 4 months ago

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

2026-01-14T15:00:20.000Z - 4 months ago

TG Therapeutics rises 12.2%

2026-01-14T14:40:22.000Z - 4 months ago

Unusually active option classes on open January 14th

BAC BIRK CLOV DVN IBRX ISRG MSTU

2026-01-13T21:30:36.000Z - 4 months ago

TG Therapeutics reports preliminary Q4 revenue $182M, consensus $182.38M

2026-01-13T21:30:27.000Z - 4 months ago

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

Jan 13, 2026, 4:30 PM EST - 4 months ago

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 4 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 5 months ago

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 28, 2025, 7:30 AM EST - 5 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 6 months ago

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 3, 2025, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025

Oct 31, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 28, 2025, 7:30 AM EDT - 6 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Sep 24, 2025, 9:10 AM EDT - 8 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 10, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 8 months ago

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 8 months ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 4, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 10:20 AM EDT - 8 months ago

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 8 months ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Aug 28, 2025, 8:00 AM EDT - 9 months ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 4, 2025, 8:30 AM EDT - 9 months ago

TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 9 months ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Jul 30, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jun 10, 2025, 10:40 AM EDT - 11 months ago

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 4:51 PM EDT - 11 months ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

Jun 6, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 12:50 PM EDT - 1 year ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Dec 3, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Nov 21, 2024, 6:00 AM EST - 1 year ago

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Nov 4, 2024, 9:00 AM EST - 1 year ago

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

Nov 4, 2024, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q3 2024

Nov 1, 2024, 8:06 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Sep 18, 2024, 7:15 AM EDT - 1 year ago

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Sep 18, 2024, 7:00 AM EDT - 1 year ago

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

Sep 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Aug 6, 2024, 9:01 AM EDT - 1 year ago

HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics

Aug 6, 2024, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

Jun 11, 2024, 1:20 PM EDT - 2 years ago

TG Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 7, 2024, 7:50 AM EDT - 2 years ago

TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 1:30 PM EDT - 2 years ago

TG Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 3, 2024, 7:30 AM EDT - 2 years ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 31, 2024, 7:30 AM EDT - 2 years ago

TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

RandandKaren May. 10 at 3:58 PM

0 · Reply

ChartistMoM May. 10 at 3:32 PM

$TGTX My son forgot about Mother’s Day! I pay off his margarine calls and this is the thanks I get. Hey, call your mom and tell her you love her! My son certainly won’t. 😪

2 · Reply

Gshc22 May. 10 at 3:03 PM

1 · Reply

DragonAlgoTrades May. 10 at 8:39 AM

0 · Reply

ACES_ May. 9 at 6:34 PM

$TGTX Just hold... dont worry.. be happy.. https://youtu.be/d-diB65scQU?si=aB0B6uzEWmbPRJi-

2 · Reply

Bobes May. 9 at 2:21 PM

6 · Reply

Thurmond May. 9 at 2:07 PM

1 · Reply

jmartin795 May. 9 at 11:06 AM

$TGTX Morning. When was the last time we saw 400k in AH trading?

2 · Reply

StockDreamin May. 9 at 4:33 AM

$TGTX Maybe maybe someday!

1 · Reply

TBLdude May. 8 at 10:23 PM

$TGTX cheers to the week… Happy Mother’s Day to the Mom’s…have a great weekend, and do something you love doing with someone you love

0 · Reply

Jxcx1990 May. 8 at 10:03 PM

$TGTX $TGTX 60 C 01/21/2028 (623D) - Prem: $200,795 - I got myself 1 con. Following the flow.

0 · Reply

PotionX1900 May. 8 at 9:15 PM

$TGTX wasn’t there some guy on here 3 or 4 weeks ago talking about his awesome scalp? “Bought in at $30 and sold at $33”. Then proceeded to say he’s out and we should be too. Like he made dramatic gains or something shit. Where is that guy? I remember commenting like “later”. See ya! I bet he’s banging his head against the desk right now.

1 · Reply

Kobe2324 May. 8 at 8:32 PM

$TGTX great week ladies and gentleman. Stay the course. Enjoy The Weekend

1 · Reply

Lions1_83 May. 8 at 8:29 PM

$TGTX Very nice week No complaints here. Let's continue our journey on Monday Have a good weekend all 💰GLTA

0 · Reply

uhk_it_im_in May. 8 at 8:26 PM

$TGTX don’t worry guys, it was just the shake out before the weekend because we’re gonna get an email on Sunday evening it says we were sold for $92 a share. PS don’t kill me if the email doesn’t come lol.

2 · Reply

calbucs May. 8 at 7:42 PM

$TGTX I guess Shortie has not given up just yet !! Cant stop this train ! They will continue to deliver big qtr after qtr !! 1b in revs coming

0 · Reply

Whiskeyunderthebed May. 8 at 7:39 PM

$TGTX what happened- we blew a tire already?

1 · Reply

ians May. 8 at 7:32 PM

$TGTX Good 1Q'26 summary from Zacks. Don't understand how supposed EPS "miss" is really a concern when Briumvi P3 trials & Azer-cel P1 trial is ongoing. 🤔 Bottom line "miss" could be an analyst forecasting mistake for all we know. 🤷‍♂️ Maybe their EPS expectations were wrong?!? ☘️💎 https://finance.yahoo.com/markets/stocks/articles/tgtx-q1-earnings-miss-sales-160800270.html

1 · Reply

Quad_ May. 8 at 7:11 PM

$TGTX I leave for a few hours and look what happens.

1 · Reply

steven1x May. 8 at 7:08 PM

$TGTX new potential ind https://g.co/gemini/share/1d9171b5a7a7

1 · Reply

SteveTexans May. 8 at 7:02 PM

$TGTX Disappointing day. Expected green run. Especially going into a weekend.

2 · Reply

steven1x May. 8 at 6:44 PM

$TGTX https://www.fool.com/earnings/call-transcripts/2026/05/06/tg-therapeutics-tgtx-q1-2026-earnings-transcript/

0 · Reply

Market Cap	6.56B
Revenue (ttm)	616.29M
Net Income (ttm)	447.18M
EPS (ttm)	N/A
PE Ratio	14.79
Forward PE	31.07
Profit Margin	72.56%
Debt to Equity Ratio	0.38

Volume	3,729,500
Avg Vol	2,157,330
Day's Range	N/A - N/A
Shares Out	153.08M
Stochastic %K	84%
Beta	1.68
Analysts	Sell
Price Target	$47.86